Hyperphosphatemia during spontaneous tumor lysis syndrome culminate in severe hypophosphatemia at the time of blast crisis of Phneg CML to acute myelomoncytic leukemia

Experimental Hematology & Oncology

Ginette Schiby⁷  Ehud Grossman³  Ninette Amariglio¹  Sara Apter⁴  Yeroham Kleinbaum⁴  Tali Tohami¹  Abraham Kneller⁶  Luba Trakhtenbrot¹  Camila Avivi⁷  Pazit Beckerman²  Eli J Holtzman²  Ophira Salomon⁵ 

[1] Hematology Laboratory, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;Institute of Nephrology and Hypertension, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;Department of Internal Medicine D, Sheba Medical Center and Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel;Department of Diagnostic Imaging, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;The Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;Institute of Hematology, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;Department of Pathology, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

关键词: Hyperphosphatemia;    Hypophosphatemia;    Apoptosis;    Tumor lysis syndrome;    Acute leukemia;   

Others  :  814676
DOI  :  10.1186/2162-3619-1-24

 received in 2012-05-30, accepted in 2012-07-30,  发布年份 2012

【 摘 要 】

Extreme swing of phosphor from severe hyperphosphatemia to severe hypophosphatemia in a patient with blast crisis of myeloid origin was the result of imbalance between massive apoptosis of leukemic cells in the context of spontaneous tumor lysis syndrome and massive production of leukemic cells with only 1% of blast in peripheral blood. The mutated p53 protein suggested acting as oncogene in the presented case and possibly affecting phosphor status.

【 授权许可】

   
2012 Salomon et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Milionis H, Pritsivelis N, Elisaf M: Marked hypophosphatemia in a patient with acute leukemia. Nephron 1999, 83:173.
• [2]Steiner M, Steiner B, Wilhelm S, Freund M, Schuff-Werner P: Severe hypophosphatmeia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation 2000, 25:1015-1016.
• [3]DeBerardinis RJ: Is cancer a disease of abnormal metabolism? New angles on an old idea. Genet Med 2008, 10:767-777.
• [4]Young IS, Bailie K, Trimble ER: Severe hypophosphatemia in a patient with acute leukemia. Ann Clin Biochem 1993, 30:326-328.
• [5]Polak R, Huisman A, Sikma MA, Kersting S: Spurious hypokalaemia and hypophosphataemia due to extreme hyperleukocytosis in a patient with a haematological malignancy. Ann Clin Biochem 2010, 47:179-181.
• [6]Tefferi A, Skoda R, Vardiman JW: Myeloproliferative neoplasmas: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009, 6:627-637.
• [7]Fend F, Horn T, Koch I, Vela T, Orazi A: Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2V617F negative neoplasma. Leuk Res 2008, 32:1931-1935.
• [8]Onida F, Ball G, Kantarjuan HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M: Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002, 95:1673-1684.
• [9]Howard SC, Jones DP, Pui CH: The tumor lysis syndrome. N Engl J Med 2011, 364:1844-1854.
• [10]Riccio B, Mato A, Olson EM, Berns JS, Luger S: Spontaneous tumor lysis syndrome in acute myeloid leukemia two cases and a review of the literature. Cancer Biol Ther 2006, 5:1614-1617.
• [11]Khurana A, McLean L, Atkinson S, Foulks CJ: The effect of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med 2008, 168(24):593-597.
• [12]Hoppman-Chaney NL, Cherry D, Holladay C, Yuhas J, Wang R, Velagaleti G: Identification of a patient with 7q32 deletion-associated acute myeloid leukemia and an incidental t(8;14). Cancer Genet Cytogenet 2010, 107:179-184.
• [13]Schaich M, Schlenk RF, Al-Ali HK, Döhner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G: Prognostic of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica 2007, 92:763-770.
• [14]Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP: Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006, 354:2006-2013.
• [15]Coyles S, Masters PW, Barnard D: Tmp/GFR and ionized calcium in the management of severe hypophosphatemia. Ann Clin Biochem 1992, 29:567-569.
• [16]Bode AM, Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004, 4:793-805.